APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cabozantinib (Cometriq)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cabozantinib (Cometriq) Market Outlook and Growth Opportunities 2026

23 December 2025190 pages

Choose your research edition.

Industry ResearchCabozantinib (Cometriq) Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Cabozantinib (Cometriq) Industry Growth and Trends Forecast to 203275 pages · $3,450 USDMarket StructureGlobal Cabozantinib (Cometriq) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cabozantinib (Cometriq) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Cabozantinib (Cometriq) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Cabozantinib (Cometriq) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cabozantinib (Cometriq) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cabozantinib (Cometriq) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cabozantinib (Cometriq) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cabozantinib (Cometriq) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cabozantinib (Cometriq) market include Exelixis, Ipsen and Takeda Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cabozantinib (Cometriq) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cabozantinib (Cometriq) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cabozantinib (Cometriq) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cabozantinib (Cometriq) market size, projected growth trends, production technologies, key applications, and end-use industries.

Cabozantinib (Cometriq) Segment by Company

Exelixis

Ipsen

Takeda Pharmaceutical

Cabozantinib (Cometriq) Segment by Type

Tablet

Capsule

Cabozantinib (Cometriq) Segment by Application

Medullary Thyroid Cancer

Renal Cell Cancer

Hepatocellular Cancer

Cabozantinib (Cometriq) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cabozantinib (Cometriq) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cabozantinib (Cometriq) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cabozantinib (Cometriq) significant trends, drivers, influence factors in global and regions.

6. To analyze Cabozantinib (Cometriq) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cabozantinib (Cometriq) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cabozantinib (Cometriq) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cabozantinib (Cometriq).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cabozantinib (Cometriq) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cabozantinib (Cometriq) industry.

Chapter 3: Detailed analysis of Cabozantinib (Cometriq) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cabozantinib (Cometriq) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cabozantinib (Cometriq) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cabozantinib (Cometriq) Industry Trends Table 2. Cabozantinib (Cometriq) Industry Drivers Table 3. Cabozantinib (Cometriq) Industry Opportunities and Challenges Table 4. Cabozantinib (Cometriq) Industry Restraints Table 5. Global Cabozantinib (Cometriq) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cabozantinib (Cometriq) Revenue Share by Company (2021-2026) Table 7. Global Cabozantinib (Cometriq) Sales Volume by Company (k units) & (2021-2026) Table 8. Global Cabozantinib (Cometriq) Sales Volume Share by Company (2021-2026) Table 9. Global Cabozantinib (Cometriq) Average Price (USD/unit) of Company (2021-2026) Table 10. Global Cabozantinib (Cometriq) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cabozantinib (Cometriq) Key Company Manufacturing Base & Headquarters Table 12. Global Cabozantinib (Cometriq) Company, Product Type & Application Table 13. Global Cabozantinib (Cometriq) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cabozantinib (Cometriq) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tablet Table 18. Significant Companies of Capsule Table 19. Global Cabozantinib (Cometriq) Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Cabozantinib (Cometriq) Sales Volume by Type (2021-2026) & (k units) Table 21. Global Cabozantinib (Cometriq) Sales Volume by Type (2027-2032) & (k units) Table 22. Global Cabozantinib (Cometriq) Sales Volume Share by Type (2021-2026) Table 23. Global Cabozantinib (Cometriq) Sales Volume Share by Type (2027-2032) Table 24. Global Cabozantinib (Cometriq) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cabozantinib (Cometriq) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Cabozantinib (Cometriq) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Cabozantinib (Cometriq) Sales Value Share by Type (2021-2026) Table 28. Global Cabozantinib (Cometriq) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Medullary Thyroid Cancer Table 30. Significant Companies of Renal Cell Cancer Table 31. Significant Companies of Hepatocellular Cancer Table 32. Global Cabozantinib (Cometriq) Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Cabozantinib (Cometriq) Sales Volume by Application (2021-2026) & (k units) Table 34. Global Cabozantinib (Cometriq) Sales Volume by Application (2027-2032) & (k units) Table 35. Global Cabozantinib (Cometriq) Sales Volume Share by Application (2021-2026) Table 36. Global Cabozantinib (Cometriq) Sales Volume Share by Application (2027-2032) Table 37. Global Cabozantinib (Cometriq) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Cabozantinib (Cometriq) Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Cabozantinib (Cometriq) Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Cabozantinib (Cometriq) Sales Value Share by Application (2021-2026) Table 41. Global Cabozantinib (Cometriq) Sales Value Share by Application (2027-2032) Table 42. Global Cabozantinib (Cometriq) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Cabozantinib (Cometriq) Sales by Region (2021-2026) & (k units) Table 44. Global Cabozantinib (Cometriq) Sales Market Share by Region (2021-2026) Table 45. Global Cabozantinib (Cometriq) Sales by Region (2027-2032) & (k units) Table 46. Global Cabozantinib (Cometriq) Sales Market Share by Region (2027-2032) Table 47. Global Cabozantinib (Cometriq) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Cabozantinib (Cometriq) Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Cabozantinib (Cometriq) Sales Value Share by Region (2021-2026) Table 50. Global Cabozantinib (Cometriq) Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Cabozantinib (Cometriq) Sales Value Share by Region (2027-2032) Table 52. Global Cabozantinib (Cometriq) Market Average Price (USD/unit) by Region (2021-2026) Table 53. Global Cabozantinib (Cometriq) Market Average Price (USD/unit) by Region (2027-2032) Table 54. Global Cabozantinib (Cometriq) Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Global Cabozantinib (Cometriq) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Cabozantinib (Cometriq) Sales by Country (2021-2026) & (k units) Table 57. Global Cabozantinib (Cometriq) Sales Market Share by Country (2021-2026) Table 58. Global Cabozantinib (Cometriq) Sales by Country (2027-2032) & (k units) Table 59. Global Cabozantinib (Cometriq) Sales Market Share by Country (2027-2032) Table 60. Global Cabozantinib (Cometriq) Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Cabozantinib (Cometriq) Sales Value Market Share by Country (2021-2026) Table 62. Global Cabozantinib (Cometriq) Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Cabozantinib (Cometriq) Sales Value Market Share by Country (2027-2032) Table 64. Exelixis Company Information Table 65. Exelixis Business Overview Table 66. Exelixis Cabozantinib (Cometriq) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 67. Exelixis Cabozantinib (Cometriq) Product Portfolio Table 68. Exelixis Recent Development Table 69. Ipsen Company Information Table 70. Ipsen Business Overview Table 71. Ipsen Cabozantinib (Cometriq) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 72. Ipsen Cabozantinib (Cometriq) Product Portfolio Table 73. Ipsen Recent Development Table 74. Takeda Pharmaceutical Company Information Table 75. Takeda Pharmaceutical Business Overview Table 76. Takeda Pharmaceutical Cabozantinib (Cometriq) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 77. Takeda Pharmaceutical Cabozantinib (Cometriq) Product Portfolio Table 78. Takeda Pharmaceutical Recent Development Table 79. Key Raw Materials Table 80. Raw Materials Key Suppliers Table 81. Cabozantinib (Cometriq) Distributors List Table 82. Cabozantinib (Cometriq) Customers List Table 83. Research Programs/Design for This Report Table 84. Authors List of This Report Table 85. Secondary Sources Table 86. Primary Sources List of Figures Figure 1. Cabozantinib (Cometriq) Product Image Figure 2. Global Cabozantinib (Cometriq) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cabozantinib (Cometriq) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cabozantinib (Cometriq) Sales (2021-2032) & (k units) Figure 5. Global Cabozantinib (Cometriq) Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Cabozantinib (Cometriq) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tablet Image Figure 10. Capsule Image Figure 11. Global Cabozantinib (Cometriq) Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Cabozantinib (Cometriq) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Cabozantinib (Cometriq) Sales Volume Share by Type (2021-2032) Figure 14. Global Cabozantinib (Cometriq) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Cabozantinib (Cometriq) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Cabozantinib (Cometriq) Sales Value Share by Type (2021-2032) Figure 17. Medullary Thyroid Cancer Image Figure 18. Renal Cell Cancer Image Figure 19. Hepatocellular Cancer Image Figure 20. Global Cabozantinib (Cometriq) Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Cabozantinib (Cometriq) Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Cabozantinib (Cometriq) Sales Volume Share by Application (2021-2032) Figure 23. Global Cabozantinib (Cometriq) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Cabozantinib (Cometriq) Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Cabozantinib (Cometriq) Sales Value Share by Application (2021-2032) Figure 26. Global Cabozantinib (Cometriq) Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 27. Global Cabozantinib (Cometriq) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Cabozantinib (Cometriq) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Cabozantinib (Cometriq) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Cabozantinib (Cometriq) Sales Value (2021-2032) & (US$ Million) Figure 31. North America Cabozantinib (Cometriq) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Cabozantinib (Cometriq) Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Cabozantinib (Cometriq) Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Cabozantinib (Cometriq) Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Cabozantinib (Cometriq) Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Cabozantinib (Cometriq) Sales Value (2021-2032) & (US$ Million) Figure 37. South America Cabozantinib (Cometriq) Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Cabozantinib (Cometriq) Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Cabozantinib (Cometriq) Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Cabozantinib (Cometriq) Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Cabozantinib (Cometriq) Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Capsule
Applications
  • Medullary Thyroid Cancer
  • Renal Cell Cancer
  • Hepatocellular Cancer
Companies covered
  • Exelixis
  • Ipsen
  • Takeda Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cabozantinib (Cometriq) Sales Value (2021-2032)
  4. 1.2.2 Global Cabozantinib (Cometriq) Sales Volume (2021-2032)
  5. 1.2.3 Global Cabozantinib (Cometriq) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cabozantinib (Cometriq) Market Dynamics
  1. 2.1 Cabozantinib (Cometriq) Industry Trends
  2. 2.2 Cabozantinib (Cometriq) Industry Drivers
  3. 2.3 Cabozantinib (Cometriq) Industry Opportunities and Challenges
  4. 2.4 Cabozantinib (Cometriq) Industry Restraints
3 Cabozantinib (Cometriq) Market by Company
  1. 3.1 Global Cabozantinib (Cometriq) Company Revenue Ranking in 2025
  2. 3.2 Global Cabozantinib (Cometriq) Revenue by Company (2021-2026)
  3. 3.3 Global Cabozantinib (Cometriq) Sales Volume by Company (2021-2026)
  4. 3.4 Global Cabozantinib (Cometriq) Average Price by Company (2021-2026)
  5. 3.5 Global Cabozantinib (Cometriq) Company Ranking (2024-2026)
  6. 3.6 Global Cabozantinib (Cometriq) Company Manufacturing Base and Headquarters
  7. 3.7 Global Cabozantinib (Cometriq) Company Product Type and Application
  8. 3.8 Global Cabozantinib (Cometriq) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cabozantinib (Cometriq) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cabozantinib (Cometriq) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cabozantinib (Cometriq) Market by Type
  1. 4.1 Cabozantinib (Cometriq) Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Capsule
  4. 4.2 Global Cabozantinib (Cometriq) Sales Volume by Type
  5. 4.2.1 Global Cabozantinib (Cometriq) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cabozantinib (Cometriq) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Cabozantinib (Cometriq) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Cabozantinib (Cometriq) Sales Value by Type
  9. 4.3.1 Global Cabozantinib (Cometriq) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Cabozantinib (Cometriq) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Cabozantinib (Cometriq) Sales Value Share by Type (2021-2032)
5 Cabozantinib (Cometriq) Market by Application
  1. 5.1 Cabozantinib (Cometriq) Application Introduction
  2. 5.1.1 Medullary Thyroid Cancer
  3. 5.1.2 Renal Cell Cancer
  4. 5.1.3 Hepatocellular Cancer
  5. 5.2 Global Cabozantinib (Cometriq) Sales Volume by Application
  6. 5.2.1 Global Cabozantinib (Cometriq) Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Cabozantinib (Cometriq) Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Cabozantinib (Cometriq) Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Cabozantinib (Cometriq) Sales Value by Application
  10. 5.3.1 Global Cabozantinib (Cometriq) Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Cabozantinib (Cometriq) Sales Value by Application (2021-2032)
  12. 5.3.3 Global Cabozantinib (Cometriq) Sales Value Share by Application (2021-2032)
6 Cabozantinib (Cometriq) Regional Sales and Value Analysis
  1. 6.1 Global Cabozantinib (Cometriq) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cabozantinib (Cometriq) Sales by Region (2021-2032)
  3. 6.2.1 Global Cabozantinib (Cometriq) Sales by Region: 2021-2026
  4. 6.2.2 Global Cabozantinib (Cometriq) Sales by Region (2027-2032)
  5. 6.3 Global Cabozantinib (Cometriq) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cabozantinib (Cometriq) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cabozantinib (Cometriq) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cabozantinib (Cometriq) Sales Value by Region (2027-2032)
  9. 6.5 Global Cabozantinib (Cometriq) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cabozantinib (Cometriq) Sales Value (2021-2032)
  12. 6.6.2 North America Cabozantinib (Cometriq) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cabozantinib (Cometriq) Sales Value (2021-2032)
  15. 6.7.2 Europe Cabozantinib (Cometriq) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cabozantinib (Cometriq) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cabozantinib (Cometriq) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cabozantinib (Cometriq) Sales Value (2021-2032)
  21. 6.9.2 South America Cabozantinib (Cometriq) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cabozantinib (Cometriq) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cabozantinib (Cometriq) Sales Value Share by Country, 2025 VS 2032
7 Cabozantinib (Cometriq) Country-level Sales and Value Analysis
  1. 7.1 Global Cabozantinib (Cometriq) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cabozantinib (Cometriq) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cabozantinib (Cometriq) Sales by Country (2021-2032)
  4. 7.3.1 Global Cabozantinib (Cometriq) Sales by Country (2021-2026)
  5. 7.3.2 Global Cabozantinib (Cometriq) Sales by Country (2027-2032)
  6. 7.4 Global Cabozantinib (Cometriq) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cabozantinib (Cometriq) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cabozantinib (Cometriq) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cabozantinib (Cometriq) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cabozantinib (Cometriq) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cabozantinib (Cometriq) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Exelixis
  2. 8.1.1 Exelixis Company Information
  3. 8.1.2 Exelixis Business Overview
  4. 8.1.3 Exelixis Cabozantinib (Cometriq) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Exelixis Cabozantinib (Cometriq) Product Portfolio
  6. 8.1.5 Exelixis Recent Developments
  7. 8.2 Ipsen
  8. 8.2.1 Ipsen Company Information
  9. 8.2.2 Ipsen Business Overview
  10. 8.2.3 Ipsen Cabozantinib (Cometriq) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ipsen Cabozantinib (Cometriq) Product Portfolio
  12. 8.2.5 Ipsen Recent Developments
  13. 8.3 Takeda Pharmaceutical
  14. 8.3.1 Takeda Pharmaceutical Company Information
  15. 8.3.2 Takeda Pharmaceutical Business Overview
  16. 8.3.3 Takeda Pharmaceutical Cabozantinib (Cometriq) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Pharmaceutical Cabozantinib (Cometriq) Product Portfolio
  18. 8.3.5 Takeda Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cabozantinib (Cometriq) Value Chain Analysis
  2. 9.1.1 Cabozantinib (Cometriq) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cabozantinib (Cometriq) Sales Mode & Process
  6. 9.2 Cabozantinib (Cometriq) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cabozantinib (Cometriq) Distributors
  9. 9.2.3 Cabozantinib (Cometriq) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst